Astec LifeSciences Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Fourth Quarter and Year Ended March 31, 2017
May 06, 2017 at 02:40 am EDT
Share
Astec LifeSciences Limited reported unaudited standalone and consolidated earnings results for the fourth quarter and year ended March 31, 2017. For the quarter, on standalone basis, the company reported total income from operations of INR 904.573 million compared to INR 824.501 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 123.519 million compared to INR 111.681 million a year ago. Profit from ordinary activities before tax was INR 41.505 million compared to INR 99.207 million a year ago. Net profit for the period was INR 34.922 million or INR 1.79 per diluted share before and after extraordinary items compared to INR 8.873 million or INR 0.45 per diluted share before and after extraordinary items a year ago.
For the year, on standalone basis, the company reported total income from operations of INR 3,127.574 million compared to INR 2,351.855 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 490.849 million compared to INR 203.848 million a year ago. Profit from ordinary activities before tax was INR 286.272 million compared to INR 75.942 million a year ago. Net profit for the period was INR 190.942 million or INR 9.77 per diluted share before and after extraordinary items compared to INR 3.538 million or INR 0.18 per diluted share before and after extraordinary items a year ago.
For the quarter, on consolidated basis, the company reported total income from operations of INR 905.025 million compared to INR 835.845 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 119.355 million compared to INR 114.040 million a year ago. Profit from ordinary activities before tax was INR 41.254 million compared to INR 147.788 million a year ago. Net profit after taxes, minority interest and share of profit of associates was INR 34.605 million or INR 1.77 per diluted share before and after extraordinary items compared to INR 56.063 million or INR 2.87 per diluted share before and after extraordinary items a year ago.
For the year, on consolidated basis, the company reported total income from operations of INR 3,134.035 million compared to INR 2,469.924 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 492.062 million compared to INR 211.631 million a year ago. Profit from ordinary activities before tax was INR 287.430 million compared to INR 124.243 million a year ago. Net profit after taxes, minority interest and share of profit of associates was INR 191.177 million or INR 9.78 per diluted share before and after extraordinary items compared to INR 49.666 million or INR 2.54 per diluted share before and after extraordinary items a year ago.
Astec LifeSciences Limited is an India-based company that is primarily engaged in manufacturing a range of agrochemical active ingredients and pharmaceutical intermediates. The Company operates through the Agrochemicals segment. It manufactures a range of fungicides, insecticides, herbicides, and intermediates for its global customers. The Companyâs products and intermediates includes triazole fungicides, heterocyclic herbicides, sulfonylurea herbicides, synthetic pyrethroids, alkyl and aryl magnesium halides, mixed metal halides, silane derivatives, fluorinated aromatic, aliphatic and heterocyclic intermediates, fluorinated aromatic amines, fluorinated pyridine derivatives, fluorinated aromatic carboxylic acids, fluorinated benzyl alcohols, fluorinated ketones and benzophenones, fluorinated heterocyclic mercaptans, heterocyclic mercaptans, thiopyrimidines, aromatic mercaptans, thorium salts, pyrazaloneâs and heterocyclic sulfonyl chlorides.
ASTEC LIFESCIENCES LIMITED 
